Recovery
Cibinetide
Also called ARA-290, EPO-derived 11-mer
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 1.67mg/mL
- Volume per draw
- 0.6mL
- Units to dial
- 60
- Doses per cartridge
- 5
Vial label
Copy this into your label printer.
Published research contexts for Cibinetide describe 1–8 mg per administration. Descriptive only, not a recommendation.
Minutes-scale in plasma; the decay chart is largely illustrative here.
Dosing schedule
How Cibinetide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Studied daily doseThe amount carried through the 28-day study. | 4 mg | Once daily | SubQ |
| Range exploredSingle ascending doses of 1, 4 and 8 mg were assessed. | 1–8 mg | Once daily | SubQ |
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 0.94× single dose
- Time to steady state
- 0hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Dahan A et al., Mol Med 2013;19:334Subcutaneous cibinetide (ARA-290) 4 mg once daily for 28 days assessed in sarcoidosis-associated small-fibre neuropathy.
- Culver DA et al., 2017Subcutaneous cibinetide at 1, 4 and 8 mg once daily assessed over 28 days for corneal nerve-fibre measures.